Immunology and Cell Biology,
Год журнала:
2024,
Номер
unknown
Опубликована: Сен. 13, 2024
Abstract
Natural
killer
(NK)
cells
play
a
vital
role
in
innate
immunity
and
show
great
promise
cancer
immunotherapy.
Traditional
sources
of
NK
cells,
such
as
the
peripheral
blood,
are
limited
by
availability
donor
variability.
In
addition,
vitro
expansion
can
lead
to
functional
exhaustion
gene
editing
challenges.
This
study
aimed
harness
induced
pluripotent
stem
cell
(iPSC)
technology
provide
consistent
scalable
source
overcoming
limitations
traditional
enhancing
potential
for
immunotherapy
applications.
We
developed
human
placental–derived
iPSC
lines
using
reprogramming
techniques.
Subsequently,
an
optimized
two‐step
differentiation
protocol
was
introduced
generate
high‐purity
cells.
Initially,
iPSCs
were
differentiated
into
hematopoietic‐like
spin‐free
embryoid
bodies
(EBs).
EBs
transferred
ultra‐low
attachment
plates
induce
differentiation.
iPSC‐derived
(iNK)
expressed
common
markers
(NKp46,
NKp30,
NKp44,
CD16
eomesodermin)
at
both
RNA
protein
levels.
iNK
demonstrated
significant
resilience
cryopreservation
exhibited
enhanced
cytotoxicity.
The
incorporation
chimeric
antigen
receptor
(CAR)
construct
further
augmented
their
cytotoxic
potential.
exemplifies
feasibility
generating
with
high
purity
capabilities,
improved
have
cytotoxicity
through
CAR
expression.
Our
findings
offer
promising
pathway
development
cellular
immunotherapies,
highlighting
critical
challenges
associated
sources.
Signal Transduction and Targeted Therapy,
Год журнала:
2024,
Номер
9(1)
Опубликована: Июль 17, 2024
Traditional
therapeutic
approaches
such
as
chemotherapy
and
radiation
therapy
have
burdened
cancer
patients
with
onerous
physical
psychological
challenges.
Encouragingly,
the
landscape
of
tumor
treatment
has
undergone
a
comprehensive
remarkable
transformation.
Emerging
fervently
pursued
modalities
are
small
molecule
targeted
agents,
antibody-drug
conjugates
(ADCs),
cell-based
therapies,
gene
therapy.
These
cutting-edge
not
only
afford
personalized
precise
targeting,
but
also
provide
enhanced
comfort
potential
to
impede
disease
progression.
Nonetheless,
it
is
acknowledged
that
these
strategies
still
harbour
untapped
for
further
advancement.
Gaining
understanding
merits
limitations
holds
promise
offering
novel
perspectives
clinical
practice
foundational
research
endeavours.
In
this
review,
we
discussed
different
modalities,
including
drugs,
peptide
antibody
cell
therapy,
It
will
detailed
explanation
each
method,
addressing
their
status
development,
challenges,
solutions.
The
aim
assist
clinicians
researchers
in
gaining
deeper
diverse
options,
enabling
them
carry
out
effective
advance
more
efficiently.
Abstract
Significant
advancements
have
been
made
in
the
application
of
chimeric
antigen
receptor
(CAR)-T
treatment
for
blood
cancers
during
previous
ten
years.
However,
its
effectiveness
treating
solid
tumors
is
still
lacking,
necessitating
exploration
alternative
immunotherapies
that
can
overcome
significant
challenges
faced
by
current
CAR-T
cells.
CAR-based
immunotherapy
against
shows
promise
with
emergence
macrophages,
which
possess
robust
phagocytic
abilities,
antigen-presenting
functions,
and
ability
to
modify
tumor
microenvironment
stimulate
adaptive
responses.
This
paper
presents
a
thorough
examination
latest
progress
CAR-M
therapy,
covering
both
basic
scientific
studies
clinical
trials.
study
examines
primary
obstacles
hindering
realization
complete
potential
as
well
strategies
be
employed
these
hurdles.
With
revolutionary
technologies
like
situ
genetic
modification,
synthetic
biology
techniques,
biomaterial-supported
gene
transfer,
provide
wider
array
resources
manipulating
tumor-associated
we
suggest
combining
advanced
methods
will
result
creation
new
era
therapy
demonstrates
improved
efficacy,
safety,
availability.
Graphical
Developmental Cell,
Год журнала:
2024,
Номер
59(9), С. 1110 - 1131.e22
Опубликована: Апрель 2, 2024
The
developmental
origin
of
blood-forming
hematopoietic
stem
cells
(HSCs)
is
a
longstanding
question.
Here,
our
non-invasive
genetic
lineage
tracing
in
mouse
embryos
pinpoints
that
artery
endothelial
generate
HSCs.
Arteries
are
transiently
competent
to
HSCs
for
2.5
days
(∼E8.5–E11)
but
subsequently
cease,
delimiting
narrow
time
frame
HSC
formation
vivo.
Guided
by
the
arterial
origins
blood,
we
efficiently
and
rapidly
differentiate
human
pluripotent
(hPSCs)
into
posterior
primitive
streak,
lateral
mesoderm,
endothelium,
hemogenic
>90%
pure
progenitors
within
10
days.
hPSC-derived
T,
B,
NK,
erythroid,
myeloid
vitro
and,
critically,
express
hallmark
transcription
factors
HLF
HOXA5-HOXA10,
which
were
previously
challenging
upregulate.
We
differentiated
hPSCs
highly
enriched
HLF+
HOXA+
with
near-stoichiometric
efficiency
blocking
unwanted
lineages
at
each
differentiation
step.
could
avail
both
basic
research
cellular
therapies.
Abstract
Neurodegenerative
diseases
(NDDs)
affect
more
than
50
million
people
worldwide,
posing
a
significant
global
health
challenge
as
well
high
socioeconomic
burden.
With
aging
constituting
one
of
the
main
risk
factors
for
some
NDDs
such
Alzheimer's
disease
(AD)
and
Parkinson's
(PD),
this
societal
toll
is
expected
to
rise
considering
predicted
increase
in
population
limited
progress
development
effective
therapeutics.
To
address
failure
rates
clinical
trials,
legislative
changes
permitting
use
alternatives
traditional
pre‐clinical
vivo
models
are
implemented.
In
regard,
microphysiological
systems
(MPS)
organ‐on‐a‐chip
(OoC)
platforms
constitute
promising
tool,
due
their
ability
mimic
complex
human‐specific
tissue
niches
vitro.
This
review
summarizes
current
modeling
using
OoC
technology
discusses
five
critical
aspects
still
insufficiently
addressed
date.
Taking
these
into
consideration
future
MPS
will
advance
vitro
translational
value
setting.
iScience,
Год журнала:
2024,
Номер
27(9), С. 110750 - 110750
Опубликована: Авг. 17, 2024
Innate
immune
cells,
crucial
in
resisting
infections
and
initiating
adaptive
immunity,
play
diverse
significant
roles
tumor
development.
These
including
macrophages,
granulocytes,
dendritic
cells
(DCs),
innate
lymphoid
innate-like
T
are
pivotal
the
microenvironment
(TME).
components
of
TME,
based
on
which
various
immunotherapy
strategies
have
been
explored.
Immunotherapy
strategies,
such
as
novel
checkpoint
inhibitors,
STING/CD40
agonists,
macrophage-based
surface
backpack
anchoring,
Journal of Experimental & Clinical Cancer Research,
Год журнала:
2025,
Номер
44(1)
Опубликована: Март 15, 2025
Abstract
In
the
last
two
decades,
novel
and
promising
cell-based
therapies
have
populated
treatment
landscape
for
haematological
tumors.
However,
commonly
exploited
T
NK
show
limited
applicability
to
solid
This
is
mainly
given
by
impaired
tumor
trafficking
capability
effector
activity
of
these
cells
within
a
highly
immunosuppressive
microenvironment.
Myeloid
spontaneously
home
tumors
can
thus
be
reprogrammed
and/or
engineered
directly
attack
or
locally
selectively
deliver
therapeutically
relevant
payloads
that
may
improve
efficacy
immunotherapy
against
difficult-to-access
context
myeloid
therapies,
adoptive
transfer
monocytes
has
often
been
overshadowed
infusion
differentiated
macrophages
hematopoietic
stem
cell
transplantation
despite
their
therapeutic
potential.
Here,
we
summarize
recent
improvements
benefits
using
tumors,
current
clinical
applications
challenges
use
as
well
some
possible
strategies
overcome
them.
